Drug Report History #265936
Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that have changed between versions will be highlighted in yellow, and the changes will be clearly marked as updated.
The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow, and the change will be clearly marked as updated.
| Field | Version v8-FR | Version v3-EN |
|---|---|---|
| Language | French (Updated) | English |
| Date Updated | 2026-03-11 (Updated) | 2026-02-03 |
| Drug Identification Number | 02389185 | 02389185 |
| Brand name | KOMBOGLYZE | KOMBOGLYZE |
| Common or Proper name | saxagliptin and metformin hydrochloride tablets | saxagliptin and metformin hydrochloride tablets |
| Company Name | ASTRAZENECA CANADA INC | ASTRAZENECA CANADA INC |
| Ingredients | SAXAGLIPTIN METFORMIN HYDROCHLORIDE | SAXAGLIPTIN METFORMIN HYDROCHLORIDE |
| Strength(s) | 2.5MG 1000MG | 2.5MG 1000MG |
| Dosage form(s) | TABLET | TABLET |
| Route of administration | ORAL ORAL | ORAL ORAL |
| Packaging size | 60 tablets | 60 tablets |
| Anatomical Therapeutical Chemical (ATC) code | A10BD | A10BD |
| Anatomical Therapeutical Chemical (ATC) description | BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS | BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS |
| Reason for discontinuation | Business reasons | Business reasons |
| Anticipated discontinuation date | 2026-03-27 (Updated) | 2026-03-15 |
| Actual discontinuation date | 2026-03-10 (Updated) | |
| Remaining supply date | 2026-03-10 (Updated) | 2026-03-15 |
| Discontinuation status | Discontinued (Updated) | To be discontinued |
| Discontinuation decision reversal | No | No |
| Tier 3 Status | No | No |
| Information on remaining supply | ||
| Company comments | ||
| Health Canada comments |